An interventional study of Vitamin D and Omega-3 in Prostate Cancer, sponsored by Case Comprehensive Cancer Center. Completed at 1 site in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2020-02-18.
Sponsored by Case Comprehensive Cancer Center · Not applicable, Interventional, and Treatment
Among 46 studies in Prostatic Neoplasms by Case Comprehensive Cancer Center — 8 open to participants now, 8 under way, none of them phase 3. Prostatic Neoplasms · Case Comprehensive Cancer Center.
Among the 46 studies in Prostatic Neoplasms by Case Comprehensive Cancer Center, this one is the 16th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2017, is one of 30 with no phase, and was the 28th registered.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 46 studies in Prostatic Neoplasms by Case Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Case Comprehensive Cancer Center · Sites in United States
Ages 55–80
Case Comprehensive Cancer Center · Sites in United States
Ages 19+
Case Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Case Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Case Comprehensive Cancer Center · Sites in United States
Ages 19+ · Men only
By country, each count listing its studies:
Of the 1,228 Prostatic Neoplasms studies recruiting now, 928 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 1
First in 1999; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 30 across the 42 interventional studies, 60 across the 4 observational. Of the 27 that completed or were terminated, 11 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
Case Comprehensive Cancer Center is the lead sponsor of 494 studies on the registry; 59 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 46 (61%) have results posted.
4 of the studies in Prostatic Neoplasms by Case Comprehensive Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07084779Case Comprehensive Cancer CenterInvestigation of Impact of AI on Prostate Cancer Workflow | 2026-11-30 |
| NCT05590624Case Comprehensive Cancer CenterMetabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer | 2026-12 |
| NCT05610852Case Comprehensive Cancer CenterSingle-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound | 2026-12-01 |
| NCT07040501Case Comprehensive Cancer CenterImproving Patient Understanding of Their Prostate Cancer Diagnosis Using AI | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies in Prostatic Neoplasms by Case Comprehensive Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if eating vitamin D, omega 3 and turmeric (curcumin) slows the growth of prostate cancer in men on active surveillance.
The primary objective is to investigate the influence of vitamin D, omega-3 fatty acids, and turmeric curcumin intake on the genomic landscape of NCCN very low and low risk patients managed with Active Surveillance. This will be measured by using genomic signatures in Decipher GRID and using the mixed effect linear model that tests for the interaction of treatment arm and time (base-line, 6 month and 12 month time points) with gene expression as the response variable.
The secondary objective is to evaluate prostate cancer aggressiveness pre and post intervention by looking at genes and gene signatures associated with vitamin D and omega-3 fatty acids pathways. Prognostic performance of GRID gene signatures will be evaluated using Active Surveillance 'Failure' (deferred treatment) as an additional endpoint.
The exploratory objective is to be able to use predictive genes and/or genomic signatures to assess benefit from vitamin D, omega-3 fatty acid and turmeric curcumin intake. This will only be possible once sufficient patient follow up is available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients are under active surveillance with no modification to their diet, as is standard of care for low risk prostate cancer
Patients receive Vitamin D, Omega-3 and turmeric curcumin as dietary supplements
Dietary Supplement: Vitamin D · Dietary Supplement: Omega-3 · Dietary Supplement: Turmeric
5000 IU/cap; One cap by mouth daily
Also known as: Vitamin D3
720 mg/cap; one capsule by mouth 3 times per day
Also known as: Omegagenics
Drug pages: Turmeric extract · Curcuma longa
250mg/cap; two capsules by mouth 4 times per day
Also known as: Turmeric curcumin
gene expression of very low and low risk prostate cancer patients on Active Surveillance
The primary objective is to investigate the influence of vitamin D, omega-3 fatty acids, and turmeric curcumin intake on the genomic landscape of NCCN very low and low risk patients managed with Active Surveillance. This will be measured by using genomic signatures in Decipher GRID and using the mixed effect linear model that tests for the interaction of treatment arm and time
Time frame: Up to 6 months
gene expression of very low and low risk prostate cancer patients on Active Surveillance
The primary objective is to investigate the influence of vitamin D, omega-3 fatty acids, and turmeric curcumin intake on the genomic landscape of NCCN very low and low risk patients managed with Active Surveillance. This will be measured by using genomic signatures in Decipher GRID and using the mixed effect linear model that tests for the interaction of treatment arm and time
Time frame: Up to 12 months
Active Surveillance Failure
Cox proportional hazards model will be used to study if genes are significantly predictive of this outcome. P-values will be corrected for multiple testing using the Benjamini-Hochberg procedure. Genes will be considered significant if the corresponding p-value is below 0.05 using a two-sided test.
Time frame: Up to 12 months
Time to Active Surveillance Failure
Time to event will be defined as time from enrollment into the study. P-values will be corrected for multiple testing using the Benjamini-Hochberg procedure.
Time frame: Up to 12 months
Ran from Sep 2017 to primary completion in Jun 2019, 21 months.
Of 1,098 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's 21 months is below that.
Counting every sponsor, half of 1,155 studies reached it within 43 months; a quarter within 22 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vitamin D · Omega-3 fatty acid
Case Comprehensive Cancer Center →